Virpax Pharmaceuticals Company Insiders

Virpax Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of (0.9142) % which means that it has lost $0.9142 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.6229) %, meaning that it created substantial loss on money invested by shareholders. Virpax Pharmaceuticals' management efficiency ratios could be used to measure how well Virpax Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.49 in 2025. Return On Capital Employed is likely to rise to -8.86 in 2025. At this time, Virpax Pharmaceuticals' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 45.3 M in 2025, whereas Other Current Assets are likely to drop slightly above 257.2 K in 2025. Common Stock Shares Outstanding is likely to rise to about 1.2 M in 2025, despite the fact that Net Loss is likely to grow to (10.3 M).

Virpax Pharmaceuticals Workforce Comparison

Virpax Pharmaceuticals Insider Trading

Virpax Pharmaceuticals Notable Stakeholders

The success or failure of an entity such as Virpax Pharmaceuticals often depends on how effective the management is. Virpax Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Virpax management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Virpax management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Virpax Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Virpax Pharmaceuticals. Check Virpax Pharmaceuticals' Beneish M Score to see the likelihood of Virpax Pharmaceuticals' management manipulating its earnings.

When running Virpax Pharmaceuticals' price analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.